Melatonin acts synergistically with pazopanib against renal cell carcinoma cells through p38 mitogen-activated protein kinase-mediated mitochondrial and autophagic apoptosis

BACKGROUND: Mounting evidence indicates that melatonin has possible activity against different tumors. Pazopanib is an anticancer drug used to treat renal cell carcinoma (RCC). This study tested the anticancer activity of melatonin combined with pazopanib on RCC cells and explored the underlying mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Chien-Pin, Chen, Yong-Syuan, Ying, Tsung-Ho, Kao, Cheng-Yen, Chiou, Hui-Ling, Kao, Shao-Hsuan, Hsieh, Yi-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Nephrology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407642/
https://www.ncbi.nlm.nih.gov/pubmed/37165617
http://dx.doi.org/10.23876/j.krcp.22.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407642/
https://www.ncbi.nlm.nih.gov/pubmed/37165617
http://dx.doi.org/10.23876/j.krcp.22.114

Ejemplares similares